

# Active substances set

**Search phrase:** nintedanib

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

## Tracheal, bronchus, and lung cancer

| | | |
|---|---|---|
| **Nintedanib** | Nintedanib is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy. | FULL REIMBURSEMENT<br>ESMO |